---
document_datetime: 2025-08-13 15:25:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/wyost-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: wyost-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.252638
conversion_datetime: 2025-12-24 20:43:24.395888
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Wyost

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 13/08/2025                          |                                             | SmPC                             | To update Section 4.8 of the SmPC to include the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000288202                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.8 of the SmPC to include the frequencies of osteonecrosis of the jaw, atypical fractures of the femur and new primary malignancy in patients with GCTB based on the results from study 20140114. In addition, the MAH took the opportunity to implement editorial changes to the PI in all languages to align   |            | frequencies of osteonecrosis of the jaw, atypical fractures of the femur and new primary malignancy in patients with GCTB based on the results from study 20140114.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000245925 | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted B.II.e.5.a.2- Type IB- To add new pack-sizes of 3 vials (EU/1/24/1812/002) and 4 vials (EU/1/24/1812/003) for 120 mg solution for injection. Furthermore, Product Information in various languages has been aligned with QRD template.                                                                                                                                                                                                                                   | 04/02/2025 | SmPC, Labelling and PL                                                                                                                                                |